Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015808 | 0.90 | GAA (0.67) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| SCHEMBL30496722 | 0.90 | GAA (0.67) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL28129391 | 0.89 | GAA (0.65) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| SCHEMBL14868335 | 0.79 | ALDH1A1 (0.60) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| SCHEMBL30226354 | 0.79 | ALDH1A1 (0.60) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| SCHEMBL2937839 | 0.79 | ALDH1A1 (0.65) | ALDH1A1GAASMN1; SMN2HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL19371392 | 0.78 | GAA (0.58) | ALDH1A1GAAALOX12SMN1; SMN2HPGD | |
| SCHEMBL17468447 | 0.77 | ALDH1A1 (0.63) | ALDH1A1GAASMN1; SMN2HPGDRAB9A | |
| SCHEMBL17198920 | 0.77 | LMNA (0.52) | ALDH1A1GAASMN1; SMN2RAB9ALMNA | |
| SCHEMBL17198858 | 0.75 | TAAR1 (0.57) | ALDH1A1GAAALOX12SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-6946141-B2 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS, INC. (US) | 2005-09-20 | — | — | US | claimed |
| EP-1389115-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | AEROVU TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12514993-B2 | Spacer device with flow rate spirometer | AEROVU TECHNOLOGIES, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250339374-A1 | BONDED MICROPARTICULATES PREPARATION AND APPLICATIONS THEREOF | VENKOR CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-6228864-B1 | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation | VIVUS, INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1027011-A1 | ADMINISTRATION OF ACTIVE AGENTS, INCLUDING 5-HT RECEPTOR AGONISTS AND ANTAGONISTS, TO TREAT PREMATURE EJACULATION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999021508-A1 | ADMINISTRATION OF ACTIVE AGENTS, INCLUDING 5-HT RECEPTOR AGONISTS AND ANTAGONISTS, TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | ALDH1A1 869/4885GAA 497/4885ALOX12 2534/4885 |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | TMCO1, CFTR, CYSLTR2 | ALDH1A1 4087/4885GAA 4774/4885ALOX12 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.